Fulvestrant: tested on its own
38 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerRecruitingNCT04263298Phase 3Report a problem
- Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.TerminatedNCT02936206Phase 1Results postedReport a problem
- Estrogen Receptor Antagonist in Patients With Pulmonary Arterial HypertensionCompletedNCT02911844Phase 2Results postedReport a problem
- A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantTerminatedNCT02540330Phase 2Results postedReport a problem
- A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedNCT02447328Phase 4Results postedReport a problem
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedNCT01602380Phase 3Results postedReport a problem
- Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenCompletedNCT01300351Phase 3Results postedReport a problem
- Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerCompletedNCT00871858Phase 2Results postedReport a problem
- Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial CancerCompletedNCT00617188Phase 2Results postedReport a problem
- Fulvestrant in Hormone Refractory Prostate CancerCompletedNCT00476645Phase 2Results postedReport a problem
- Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.CompletedNCT00334295Phase 2Results postedReport a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgCompletedNCT00313170Phase 2Results postedReport a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgCompletedNCT00305448Phase 2Results postedReport a problem
- Faslodex in McCune-Albright SyndromeCompletedNCT00278915Phase 2Results postedReport a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedNCT00274469Phase 2Results postedReport a problem
- Fulvestrant in Treating Patients With Recurrent Prostate CancerTerminatedNCT00217464Phase 2Results postedReport a problem
- Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Active, not recruitingNCT00099437Phase 3Results postedReport a problem
- Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial CancerStatus unknownNCT00006903Phase 2Results postedReport a problem
- Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic StudyCompletedNCT06074757Phase 1Report a problem
- FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia StudyCompletedNCT03926936Phase 2Report a problem
- Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM AdministrationCompletedNCT03324061Phase 1Report a problem
- The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerStatus unknownNCT03202862Phase 2Report a problem
- Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female SubjectsCompletedNCT02795039Phase 1Report a problem
- Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer PatientsStatus unknownNCT02646735Phase 2Report a problem
- Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC PatientsStatus unknownNCT02383030Phase 3Report a problem
- Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerStatus unknownNCT02000193Phase 2Report a problem
- Molecular Imaging of Fulvestrant Effects on Availability of ER Binding SitesCompletedNCT01377324Phase 2Report a problem
- A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)Status unknownNCT00927511Phase 2Report a problem
- Efficacy and Safety of 500mg of FulvestrantActive, not recruitingNCT00585507Phase 2Report a problem
- Faslodex 500mg Multiple Dose Tolerability Study in BC PatientsCompletedNCT00328120Phase 1Report a problem
- SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast CancerCompletedNCT00272740Phase 2Report a problem
- Fulvestrant in Treating Patients With Advanced Prostate CancerCompletedNCT00244998Phase 2Report a problem
- A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast CancerCompletedNCT00241449Phase 3Report a problem
- Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast CancerCompletedNCT00146601Phase 2Report a problem
- Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast CancerCompletedNCT00093002Phase 2Report a problem
- The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast CancerCompletedNCT00065325Phase 3Report a problem
- ICI 182780 in Treating Women With Metastatic Breast CancerCompletedNCT00012025Phase 2Report a problem
- ICI 182780 in Treating Women With Stage I or Stage II Primary Breast CancerTerminatedNCT00010153Phase 3Report a problem